Cardlytics, Inc. (NASDAQ:CDLX) CEO Sells $87,036.95 in Stock

Cardlytics, Inc. (NASDAQ:CDLX) CEO Amit Gupta sold 22,607 shares of Cardlytics stock in a transaction that occurred on Thursday, October 24th. The shares were sold at an average price of $3.85, for a total transaction of $87,036.95. Following the completion of the sale, the chief executive officer now owns 178,519 shares of the company’s stock, valued at $687,298.15. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Amit Gupta also recently made the following trade(s):

• On Wednesday, October 2nd, Amit Gupta sold 7,543 shares of Cardlytics stock. The shares were sold at an average price of $3.08, for a total transaction of $23,232.44.

Cardlytics Stock Up 2.6 %

Shares of CDLX stock opened at $3.88 on Friday. Cardlytics, Inc. has a 12 month low of $2.89 and a 12 month high of $20.52. The company has a quick ratio of 1.77, a current ratio of 1.77 and a debt-to-equity ratio of 1.01. The firm has a market cap of $189.28 million, a PE ratio of -0.88 and a beta of 1.67. The stock has a 50 day moving average of $3.61 and a 200-day moving average of $7.25.

Cardlytics (NASDAQ:CDLX) last released its earnings results on Wednesday, August 7th. The company reported ($0.09) EPS for the quarter, beating the consensus estimate of ($0.21) by $0.12. The firm had revenue of $69.64 million during the quarter, compared to analysts’ expectations of $75.39 million. Cardlytics had a negative net margin of 50.21% and a negative return on equity of 17.96%. The business’s quarterly revenue was down 9.2% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.57) EPS. On average, equities analysts predict that Cardlytics, Inc. will post -1.72 EPS for the current year.

Institutional Investors Weigh In On Cardlytics

Hedge funds have recently made changes to their positions in the stock. Canton Hathaway LLC raised its holdings in Cardlytics by 95.7% in the 2nd quarter. Canton Hathaway LLC now owns 4,500 shares of the company’s stock valued at $37,000 after acquiring an additional 2,200 shares in the last quarter. SG Americas Securities LLC acquired a new stake in shares of Cardlytics during the 3rd quarter worth approximately $45,000. Creative Planning increased its position in shares of Cardlytics by 35.4% during the third quarter. Creative Planning now owns 29,537 shares of the company’s stock valued at $95,000 after purchasing an additional 7,721 shares during the period. XTX Topco Ltd acquired a new position in shares of Cardlytics in the second quarter valued at $107,000. Finally, Quest Partners LLC lifted its position in Cardlytics by 160.4% in the second quarter. Quest Partners LLC now owns 17,956 shares of the company’s stock worth $147,000 after purchasing an additional 11,061 shares during the period. Institutional investors own 68.10% of the company’s stock.

Analyst Ratings Changes

CDLX has been the topic of several analyst reports. Northland Capmk downgraded shares of Cardlytics from a “strong-buy” rating to a “hold” rating in a research report on Friday, August 16th. Evercore ISI began coverage on Cardlytics in a report on Friday, October 11th. They set an “in-line” rating and a $4.00 price objective on the stock. Needham & Company LLC lowered Cardlytics from a “buy” rating to a “hold” rating in a report on Thursday, August 8th. Lake Street Capital downgraded Cardlytics from a “buy” rating to a “hold” rating and lowered their price target for the company from $18.00 to $5.00 in a report on Thursday, August 8th. Finally, Bank of America cut shares of Cardlytics from a “neutral” rating to an “underperform” rating and reduced their price objective for the stock from $4.00 to $3.50 in a research note on Thursday, August 15th. One equities research analyst has rated the stock with a sell rating and six have assigned a hold rating to the stock. According to data from MarketBeat, Cardlytics currently has a consensus rating of “Hold” and a consensus target price of $6.92.

About Cardlytics

Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.